Timo Ilari Veromaa
Chairman bei HERANTIS PHARMA OYJ
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Henri Juhani Huttunen | M | - |
Hermo Pharma Oy
Hermo Pharma Oy Pharmaceuticals: MajorHealth Technology Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd. | 16 Jahre |
Pekka Ilmari Simula | M | 50 |
Suomen Bioteollisuus ry
Laurantis Pharma Oy
Laurantis Pharma Oy Pharmaceuticals: MajorHealth Technology Laurantis Pharma Oy engages in the development of pharmaceutical products. The company was founded in July 2008 and is headquartered in Turku, Finland.
Hermo Pharma Oy
Hermo Pharma Oy Pharmaceuticals: MajorHealth Technology Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd. | 11 Jahre |
Frans Gustaf Wuite | M | 64 | 10 Jahre | |
Timo Antero Lappalainen | M | 62 |
Kemianteollisuus ry
| 16 Jahre |
Hilde Furberg | F | 65 | 3 Jahre | |
Mats Johan Peter Thorén | M | 53 | 4 Jahre | |
Antti Vuolanto | M | - | 6 Jahre | |
Antero Kallio | M | 64 | 19 Jahre | |
Petri Rolig | M | 61 |
Kemianteollisuus ry
| - |
Elina Katariina Engman | F | 54 |
Kemianteollisuus ry
| 17 Jahre |
Paula Kaarina Salastie | F | 46 |
Kemianteollisuus ry
| - |
Tero Hemmilä | M | 57 |
Kemianteollisuus ry
| 14 Jahre |
Antti Matti Korpiniemi | M | 63 |
Kemianteollisuus ry
| - |
Tone Kvåle | F | 55 | 4 Jahre | |
Manu Antero Salmi | M | 49 |
Kemianteollisuus ry
| - |
Ronald Cohen | M | 68 | 8 Jahre | |
Ari Tapio Lehtoranta | M | 61 |
Kemianteollisuus ry
| - |
Jorma Mikkonen | M | 61 |
Kemianteollisuus ry
| 3 Jahre |
Alexander Wilhelm Rosenlew | M | 53 |
Kemianteollisuus ry
| 6 Jahre |
Erkki Alfred Ville Solja | M | 70 |
Kemianteollisuus ry
| 23 Jahre |
Wolfgang Heinz Büchele | M | 64 |
Kemianteollisuus ry
| 11 Jahre |
Aki Pellervo Prihti | M | 53 | 10 Jahre | |
Nina Marietta Kopola | F | 64 |
Kemianteollisuus ry
| - |
Pekka Kaivola | M | 74 |
Kemianteollisuus ry
| - |
Erkki Olavi Järvinen | M | 64 |
Kemianteollisuus ry
| 14 Jahre |
Kim Gran | M | 70 |
Kemianteollisuus ry
| 17 Jahre |
Jane Wasman | F | 67 | 8 Jahre | |
Petri Eero Castrén | M | 62 |
Kemianteollisuus ry
| - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Pekka Allan Antero Mattila | M | 65 |
Hermo Pharma Oy
Hermo Pharma Oy Pharmaceuticals: MajorHealth Technology Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd.
Laurantis Pharma Oy
Laurantis Pharma Oy Pharmaceuticals: MajorHealth Technology Laurantis Pharma Oy engages in the development of pharmaceutical products. The company was founded in July 2008 and is headquartered in Turku, Finland. | 1 Jahre |
Kristian Rantala | M | 48 | 6 Jahre | |
Merja Tuulikki Karhapää | F | 62 | - | |
David John Cook | M | 57 | 3 Jahre | |
Markku Tapani Jalkanen | M | 70 | 10 Jahre | |
Craig Cook | M | 57 | - | |
Peter John Fellner | M | 80 | 5 Jahre | |
William Burns | M | 76 | 5 Jahre | |
Thomas Taapken | M | 59 | 3 Jahre | |
Ingrid Atteryd Heiman | F | 66 | - | |
Ismail Kola | M | 67 | - | |
Ari-Pekka Laitsaari | M | - |
Hermo Pharma Oy
Hermo Pharma Oy Pharmaceuticals: MajorHealth Technology Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd. | 4 Jahre |
James Phillips | M | 61 | - | |
Guido Magni | M | 70 | - | |
Piet Serrure | M | 70 | - | |
Mahendra Shah | M | 79 | - | |
Juha Heikki Tapio Jouhki | M | 58 | - | |
Don Bailey | M | 78 | 1 Jahre | |
Bernd Kastler | M | 75 | - | |
Krish S. Krishnan | M | 59 | 1 Jahre | |
Magnus Sjoegren | M | - | - | |
Burkhard Blank | M | 69 | - | |
Mehdi Paborji | M | 69 | 3 Jahre | |
Mikko Kuokkanen | M | - |
Hermo Pharma Oy
Hermo Pharma Oy Pharmaceuticals: MajorHealth Technology Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd. | - |
Sigrid Booms | F | - |
Hermo Pharma Oy
Hermo Pharma Oy Pharmaceuticals: MajorHealth Technology Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd. | 3 Jahre |
Magnus Sjögren | M | 60 | - | |
Liisa Hurme | M | 57 |
Suomen Bioteollisuus ry
| 6 Jahre |
Ann Hanham | M | 71 | 1 Jahre | |
James Shannon | M | 67 | 2 Jahre | |
Charlotte Videbaek | M | 62 | - | |
Chris Piggott | M | 72 | - | |
Jyrki Pekka Sakari Mattila | M | 69 |
Hermo Pharma Oy
Hermo Pharma Oy Pharmaceuticals: MajorHealth Technology Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd. | 2 Jahre |
Milla Maria Koistinaho | M | - |
Suomen Bioteollisuus ry
| 10 Jahre |
Kai Lähdesmäki | M | - | 10 Jahre | |
Bradley Bolzon | M | 64 | - | |
Panu Miettinen | M | 56 | - | |
Andrew Schwab | M | 53 | - | |
Liisa Helena Harjula | F | 52 |
Schering Oy
| 7 Jahre |
Christoph Schröder | M | 63 | - | |
Stephen L. Bandak | M | 74 | 5 Jahre | |
Tomi Juhani Numminen | M | 53 |
Schering Oy
| 5 Jahre |
Riku Heikki Rautsola | M | 69 | 7 Jahre | |
Ian John Massey | M | 73 | - | |
Thomas Kronbach | M | 72 | - | |
Mart Saarma | M | - |
Hermo Pharma Oy
Hermo Pharma Oy Pharmaceuticals: MajorHealth Technology Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd. | 1 Jahre |
Pauli Matias Marttila | M | 66 | 6 Jahre | |
J. Kenneth Charles Knowles | M | 77 |
Hermo Pharma Oy
Hermo Pharma Oy Pharmaceuticals: MajorHealth Technology Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd. | 4 Jahre |
Outi Lahdenpera | F | - | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Finnland | 76 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Timo Ilari Veromaa
- Persönliches Netzwerk